Clinical Trials Logo

Clinical Trial Summary

The problem of interest is that doctors are looking for new antibiotic treatments for bone and joint infections. Treatment for bone and joint infection is not standardized, which allows a wide range of antibiotic therapy to potentially be given. A type of bacteria called S. aureus is the most common cause of bone and joint infection. Methicillin resistant S. aureus (MRSA) is a type of bacteria that is not killed by some antibiotics, and it is increasingly common in U.S. and non-U.S. medical centers. This problem will be studied by investigating whether an antibiotic called tedizolid is tolerable, safe and effective to treat bone and joint infections.


Clinical Trial Description

The problem of interest is that doctors are looking for new antibiotic treatments for bone and joint infections. Treatment for bone and joint infection is not standardized, which allows a wide range of antibiotic therapy to potentially be given. A type of bacteria called S. aureus is the most common cause of bone and joint infection. Methicillin resistant S. aureus (MRSA) is a type of bacteria that is not killed by some antibiotics, and it is increasingly common in U.S. and non-U.S. medical centers. Trauma-associated bone and joint infection is also a common problem. Victims of major trauma often suffer bone fractures, which require temporary or permanent use of metal or other synthetic devices such as external-fixation pins, plates, and screws. These synthetic devices can also get infected and cause bone and joint infections. This problem will be studied by investigating whether an antibiotic called tedizolid is tolerable, safe and effective to treat bone and joint infections. Tedizolid is a new FDA-approved antibiotic, and can be given through the bloodstream via an IV or orally in the form of a pill. Tedizolid has less side effects compared to linezolid and is effective against types of bacteria like S. aureus. Other research also suggests that the side effects associated with long-term therapy of older types of antibiotics may not be found with tedizolid. This study will advance scientific knowledge of antibiotic treatments for bone and joint infections. Given the large and increasing burden of disease of bone and joint infection and the increasing acceptability of oral antibiotics for its management, tedizolid holds promise as a good option for patients with bone and joint infection. Harbor-UCLA Medical Center is a large medical center in the County of Los Angeles, the most populous County in the United States. The Infectious Disease consult service sees many bone and joint infections. Use of prolonged antibiotics is common in this setting. The investigators believe tedizolid addresses the unmet need for an oral antibiotic that is well-tolerated and efficacious for use as a prolonged therapy for bone and joint infection. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03009045
Study type Interventional
Source Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 6, 2017
Completion date January 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04538053 - BonE and Joint Infections - Simplifying Treatment in Children Trial Phase 4
Recruiting NCT04563325 - Oral-only Antibiotics for Bone and Joint Infections in Children Phase 4
Not yet recruiting NCT04976049 - Use of 5-Aminolevulinic Acid to Assess Bone and Tissue Profusion in Orthopaedic Infection Patients
Completed NCT03627000 - Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection
Completed NCT03311113 - Adherence to Oral Antibiotics In Patients With Osteoarticular Infections
Completed NCT03209921 - Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections N/A
Recruiting NCT04418882 - Septic Management and Outcome of Open Fracture
Completed NCT03624855 - Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France
Recruiting NCT04496024 - Ofloxacin Concentration-toxicity Relationship in the Elderly N/A
Recruiting NCT04933344 - Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
Completed NCT04373278 - Infection After Free Fibula Flap Reconstruction of the Mandible: a Retrospective Cohort Study
Completed NCT03209934 - Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center N/A
Recruiting NCT02817711 - Lyon BJI Cohort Study N/A
Recruiting NCT03611634 - Consitution Of A Biological Collection From Samples From The Gut Microbiote In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine
Completed NCT03177369 - Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration N/A
Completed NCT03852784 - Osteoarticular Infections With Pneumococcal
Completed NCT03848104 - Evaluation of the Use of Cefoxitin in Combination in Continuous Parenteral Administration in the Treatment of Bone and Joint Infections
Completed NCT03850548 - Chronic Infections on Articular Prostheses With C. Acnes Diagnosed by Specific PCR
Completed NCT03808285 - Denosumab Related Osteonecrossi of the Jaw : : an Emergent and Potentially Complex Bone and Joint Infection
Recruiting NCT03796104 - Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR